Today: 12 June 2026
Browse Category

NYSE:LLY 15 November 2025 - 6 December 2025

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly shares traded near $1,010 on December 6, 2025, with a market value just under $1 trillion after a brief pullback from record highs. The company cut list prices on Zepbound vials this week, pressuring margins and sending the stock lower. Zepbound and Mounjaro generated $10.1 billion in Q3 sales, making Lilly’s GLP-1 drugs the world’s top-selling franchise. Most analysts maintain Buy ratings, with 12-month targets around $1,060–$1,090.
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly shares traded above $1,000 on December 5, 2025, after recently crossing a $1 trillion market cap, the first for a healthcare company. The stock is up over 30% year to date despite an 8% pullback in the past week. Lilly is cutting prices on its obesity drug Zepbound and preparing to seek accelerated approval for a new weight-loss pill. The company’s dividend yield remains around 0.6%.
5 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.
2 December 2025
··
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly shares traded near $1,075 on December 1, 2025, giving the company a market cap of about $1.02 trillion, the first for a pharmaceutical firm. The company cut prices on its obesity drug Zepbound, lowering the starting dose to $299 per month from $349. Lilly’s GLP-1 drugs generated over $10 billion in Q3 revenue. The stock trades at over 70 times trailing earnings.
1 December 2025
··
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly shares closed at $1,075.47 on Friday, down 2.6% after a month-long rally that briefly pushed its market value above $1 trillion. The stock remains up about 39% year-to-date and surged roughly 26–31% in November, driven by demand for its obesity drugs. Investors are weighing recent policy headlines and valuation concerns ahead of Monday’s open. No pre-market quote was available with US markets closed over the weekend.
30 November 2025
··
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly closed Friday at $1,075 per share, capping a November surge that pushed its market value above $1 trillion—the first for a pharmaceutical company. Shares rose about 26% in November and are up over 40% in 2025. Investors are debating whether the stock, trading at a trailing P/E of 70, can sustain further gains amid strong demand for its GLP-1 obesity drugs.
30 November 2025
··
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly shares closed at $1,075.47 on November 28, down 2.6%, pulling the S&P 500 healthcare sector lower despite gains in the broader market. The stock remains up over 30% for November and more than 40% year-to-date, with a market cap around $1 trillion. JPMorgan raised its price target to $1,150. Recent gains followed strong Q3 earnings and surging sales of Mounjaro and Zepbound.
29 November 2025
··
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly shares fell 2.61% to about $1,075.47 on November 29, 2025, continuing a pullback from record highs reached earlier in the month. The company’s market cap stands near $989 billion, with shares still up roughly 43% for the year after a surge fueled by strong Q3 results and demand for obesity drugs. Trading volume was around 2.73 million shares. The stock remains priced at a P/E ratio above 50.
29 November 2025
··
Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath?

Eli Lilly shares fell about 2.5% to $1,077 in light trading Friday, a week after becoming the first drugmaker to hit a $1 trillion market value. The stock remains up 33% year-to-date and trades near its record high. Mounjaro and Zepbound drove over $10 billion in quarterly sales, more than half of company revenue. Lilly recently reached a deal with the U.S. government to expand access to its obesity drugs.
28 November 2025
·
Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

U.S. stock futures rose early Wednesday, with Dow, S&P 500, and Nasdaq futures up 0.2%–0.35% as traders bet on a December Fed rate cut. Nvidia and AMD slipped on news of an Alphabet–Meta AI chip partnership. Apple gained after a rebound in China iPhone sales. Eli Lilly hovered near a $1 trillion valuation on strong demand for weight-loss drugs.
26 November 2025
·····
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly shares closed at $1,092.4 on Tuesday, up over 2%, after Bernstein raised its price target to $1,300 citing optimism for the obesity drug orforglipron. The stock’s market value stands near $1 trillion, with shares up more than 50% in three months and trading above the average analyst target. Trading volume was about 1.2 million shares.
25 November 2025
··
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly shares traded near $1,070 Monday, up 0.9%, with market cap around $960 billion after briefly topping $1 trillion last week—the first healthcare firm to do so. Bernstein raised its price target to $1,300, citing strong obesity drug prospects. Novo Nordisk’s Alzheimer’s trial failure shifted GLP-1 sentiment. Lilly reported new Phase 2 weight-loss drug data showing up to 20% body-weight reduction.
24 November 2025
·
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market capitalization, with shares trading near $1,058 on Monday. The surge follows strong demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, both based on tirzepatide. Lilly’s stock has climbed over 35% in 2025 and more than 75% since Zepbound’s late 2023 launch. The company now trades at about 50 times expected earnings.
24 November 2025
···
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly closed Friday at about $1,060 per share, briefly topping a $1 trillion market cap—the first drugmaker to do so. Institutional filings released Sunday show Coldstream Capital raised its stake by 43.5% in Q2, while Charles Schwab Investment Management increased holdings to 5.36 million shares. LLY is up over 35% year-to-date, driven by demand for its GLP-1 obesity drugs.
23 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly closed Friday, November 21, 2025, with a market value near $1 trillion, the first drugmaker to reach that mark. Shares ended around $1,060, just below their all-time high. The surge follows strong demand for its obesity and diabetes drugs, which now generate over $10 billion in quarterly sales. Year-to-date, the stock is up about 36%.
22 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

US Stock Market Today, November 22, 2025: Wall Street Ends a Wild Week Higher as Fed Cut Bets Rise and AI Rally Shows Cracks

The Dow Jones, S&P 500, and Nasdaq all jumped over 0.9% Friday, November 21, but still closed the week lower, with losses ranging from 1.9% to 2.7%. A shift in Federal Reserve rate-cut expectations fueled the rally after New York Fed President John Williams signaled a possible cut in December. Eli Lilly reached a $1 trillion valuation, the first for a healthcare company. US stock futures rose Friday evening.
22 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Eli Lilly shares traded near $1,025 on Nov. 15, valuing the company just under $1 trillion. The White House announced a deal to lower Zepbound prices and expand public access, while Lilly expects FDA approval of its oral GLP‑1 pill by March 2026. Q3 revenue rose 54% to $17.6 billion. Lilly Endowment filed stock sales around the $1,000 level this month.
15 November 2025
·
1 … 8 9 10 11 12 13

Stock Market Today

  • USDA Boosts Argentina Soybean Production, Weighing on Soybean Prices
    June 12, 2026, 8:43 AM EDT. Soybeans fell modestly on Thursday, with cash prices down 7 3/4 cents to $10.61 1/2 amid an increase in Argentina's production forecast by the U.S. Department of Agriculture (USDA). The USDA raised Argentina's soybean output by 2 million metric tons (MMT) to 50 MMT, contributing to a global supply surplus and higher world ending stocks for 2025/26. U.S. export sales for soybeans declined 23.7% week-on-week but remained above last year's levels. Soymeal futures showed mixed results, while soy oil futures dropped. Brazil's production was steady at 180 MMT. The USDA's World Agricultural Supply and Demand Estimates (WASDE) report signaled stable U.S. old and new crop stocks, with a slight internal adjustment. Market participants are adjusting to the increased international supplies amid ongoing trade demand.

Latest articles

Richtech Robotics Stock Drops After Restatement Warning

Richtech Robotics Stock Drops After Restatement Warning

12 June 2026
Richtech Robotics plunged up to 10% premarket after disclosing that audited financial statements for 2024, 2025, and multiple quarters should not be relied upon, citing errors tied to warrant liabilities, a SEPA, and restricted stock awards; investors now await amended filings and Nasdaq compliance updates as valuation remains uncertain.
National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

12 June 2026
National Grid shares slipped 0.41% to 1,203p, underperforming the FTSE 100, as investors weighed the impact of UK grid-connection reforms that boost long-term investment prospects but increase execution risk; next catalysts are the July AGM/dividend vote and November half-year results, with analysts’ median 12-month target at 1,388.5p, about 15% above current levels.
Go toTop